MetaVisor

Tal Gavoli and his co-founders—Oran Fierst (ex-faculty of Yale and Columbia, serial health tech entrepreneur) and Professor Steve Kaplan (renowned urologist and researcher)—all encountered the same problem: family members with serious illness struggling to make sense of healthcare information. When Gavoli's own daughter required a heart transplant, he realized patients desperately needed access to cutting-edge, personalized medical information but were instead overwhelmed by generic, outdated, and unreliable data from sites like WebMD. They founded MetaVisor in late 2012 to solve this problem.

The team launched in summer 2013 after building out their core technology. They created a patent-pending system that asks patients targeted questions about their condition and treatment journey—typically 10 general questions plus 15 condition-specific questions—to build a medical profile. This profile then allows their algorithms to filter through massive databases of research (they reference 42,000 published papers on diabetes alone and 1,688 clinical trials for breast cancer) and surface only what's personally relevant. The company eventually grew to 7 full-time staff with roughly 35 part-time contributors around the world—researchers, content creators, and algorithm trainers who continuously refine the system.

MetaVisor operates on a dual-revenue model. First, they license their technology and content to major health organizations—the Leukemia and Lymphoma Society and healthcare providers—who integrate the personalized information into their platforms and charge subscribers a monthly fee. Second, they partner with biopharma companies who need to identify and recruit patients for clinical trials, a market where pharma spends billions annually. The biopharma model proved highly effective: the last four major deals came inbound—customers discovered MetaVisor online and closed within three months with no traditional sales effort. The typical biopharma deal is around $80-90K for year-one contracts, structured as longer-term engagements (sometimes clinical trial-specific six-figure deals).

Inbound leads from biopharma partners became their biggest early win—four high-value deals closing in the past 6-12 months without active sales outreach, suggesting strong product-market fit in that segment. The 50-50 split between licensing and biopharma revenue streams provided diversification, though licensing deals remained rarer ("a handful") compared to biopharma. However, the founders recognized they wouldn't sustain growth without an active sales team for biopharma, as organic discovery alone wouldn't maximize market opportunity. The personalization model—where partners could license unpersonalized content cheaply, then refer patients back to MetaVisor for premium personalization—created an effective funnel to grow their 130,000-subscriber base across 129 countries.

By the time of this interview, MetaVisor had raised $1-5M from angel investors (convertible notes converted to equity) and was raising additional capital to reach profitability within 12 months of their next round. Based on the revealed numbers—roughly 4 biopharma deals at ~$80K each (≈$320K) representing 50% of revenue—the company was estimated to be running at approximately $600-700K in annual revenue run rate, though Gavoli declined to confirm exact figures. The company was not yet profitable but had clear visibility to it, with a team spanning 7 full-time staff plus 35 global contributors continuously improving their algorithms, content, and research synthesis capabilities.